Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction

Japanese Journal of Clinical Oncology

Volumn 40, Issue 8, 2010, Pages 739-745

  Hisanaga, Takayuki ^a   Shinjo, Takuya ^b   Morita, Tatsuya ^c   Nakajima, Nobuhisa ^d   Ikenaga, Masayuki ^e   Tanimizu, Masahito ^f   Kizawa, Yoshiyuki ^g   Maeno, Takami ^g   Shima, Yasuo ^a   Hyodo, Ichinosuke ^g  

^a TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^b Kobe College   (Japan)

^c SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^d Tenshi Hospital   (Japan)

^e YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Malignant bowel obstruction; MD Anderson Symptoms Inventory; Octreotide; Subjective abdominal symptoms

Indexed keywords

CHLORPHENIRAMINE; CHLORPROMAZINE; FENTANYL; HALOPERIDOL; METOCLOPRAMIDE; MORPHINE; OCTREOTIDE; PROCHLORPERAZINE; SCOPOLAMINE BUTYL BROMIDE; STEROID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BILE DUCT CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM OBSTRUCTION; ENDOMETRIUM CANCER; FATIGUE; FEMALE; GALLBLADDER CANCER; HUMAN; INOPERABLE CANCER; INTESTINE OBSTRUCTION; KURIHARA FACE SCALE; LARGE INTESTINE OBSTRUCTION; LONG TERM CARE; MALE; MD ANDERSON SYMPTOMS INVENTORY; MULTICENTER STUDY; NAUSEA; OVARY CANCER; PANCREAS CANCER; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SELF EVALUATION; SMALL INTESTINE OBSTRUCTION; STOMACH CANCER; STOMACH OBSTRUCTION; SURVIVAL TIME; TERMINALLY ILL PATIENT; UTERINE CERVIX CANCER; VOMITING;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANOREXIA; ANTIEMETICS; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; OCTREOTIDE; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL RATE; VOMITING;

EID: 77955263906     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq048     Document Type: Article

References (16)

1. Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007;33:217-23.
2. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001;9:223-33.
3. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer 2008;48:1105-15.
4. Anthone GJ, Bastidas JA, Orandle MS, Yeo CJ. Direct proabsorptive effect of octreotide on ionic transport in the small intestine. Surgery 1990;108:1136-41.
5. Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y. A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient. Gan To Kagaku Ryoho 2004;31:1377-82.
6. Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994;30A:28-30.
7. Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 1996;61:345-8.
8. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med 1993;7:295-9.
9. Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol 2008;38: 354-9.
10. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-46.
11. Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, et al. Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 2003;26:1093-104.
12. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 1999;8:355-63.
13. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff LA. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer 2000;8:188-91.
14. Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage 2000;19:23-34.
15. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage 1992;7:496-8.
16. Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol Suppl 1986;119:65-72.